It appears to be safe for clinicians to consider testosterone therapy for symptomatic men with testosterone deficiency and a history of prostate cancer, according to new data presented at the AUA annual meeting in San Francisco.
“There is apparent promise here. There appears to be stability of results in those patients followed up,” says researcher Roger Dmochowski, MD.
It appears that many patients who have a good response to initial injections and subjective improvement fail to return for subsequent injections.
The investigational oncolytic immunotherapy CG0070 produced an overall 30% complete response rate at 12 months for patients with high-risk BCG-unresponsive non-muscle-invasive bladder cancer.
The treatment method may delay need for systemic therapy in men with oligometastatic prostate cancer.
A new study examining gene expression assays for stratifying prostate cancer risk is suggesting that it may be possible to develop lower-cost alternatives and expand access.
“The high initial complete response rate and durability observed in the interim analysis is very promising and suggests that UGN-101 could be an effective and well-tolerated noninvasive treatment for patients with UTUC,” says researcher Seth Paul Lerner, MD.
Data from a recent study also indicate that overactive bladder patients discontinue pharmacotherapy long-term despite chronic symptoms.
Until now there has been no large, thorough investigation into the risk of clean intermittent catheterization in patients undergoing repeat injections of onabotulinumtoxinA.
General urologists are less likely to utilize third-line interventions for overactive bladder than those with additional female pelvic medicine and reconstructive surgery training.